

# ANTIMICROBIAL STEWARDSHIP PROGRAM (ASP) FOR THE INFECTION CONTROL PRACTITIONER

RABEE ADWAN MD.



# OBJECTIVES

- **Identify current antimicrobial practice guidelines**
- **Identify The Role Of IPAC in ASP**

# FACT

- One of the greatest achievements in science and medicine of the last century was the discovery and the subsequent development of antibiotics for human use.

# ANTIMICROBIAL RESISTANCE: A GROWING PROBLEM

DONEC QUIS NUNC



- In 2004, approximately 2 million people experienced a hospital-acquired infection
- 90,000 of these infections were fatal
- 1 death every six minutes
- The WHO has identified antimicrobial resistance as 1 of the 3 greatest threats to human health.




# GAZZA, SYRIA, IRAQ.....



# INTRODUCTION

- Antibiotic misuse is a serious patient safety concern and a national public health priority.
- Improper antibiotic use have led to selection of antibiotic-resistant bacteria and Clostridium difficile infection, which ultimately led to poor patient outcomes.
- It is estimated that up to 50% of antimicrobial use is inappropriate in acute care settings and
- up to 75% of antibiotic use in inappropriate in long-term care facilities.

## Resistant Strains Spread Rapidly



Source: Centers for Disease Control and Prevention

MRSA = Methicillin-resistant *Staphylococcus Aureus*


VRE = Vancomycin-resistant Enterococci

FQRP = Fluoroquinolone-resistant *Pseudomonas aeruginosa*

# 12 Steps to Prevent Antimicrobial Resistance: Hospitalized Adults

*Clinicians hold the solution...*

*Take steps NOW to prevent antimicrobial resistance!*



?

?

?

?

?

WHAT IS:

ANTIMICROBIAL STEWARDSHIP?

?

?

# ASP

ARE DESIGNED TO PROMOTE JUDICIOUS USE OF  
ANTIMICROBIALS BY OPTIMIZING ANTIMICROBIAL SELECTION,  
DOSE, ROUTE, AND DURATION.

# ANTIMICROBIAL STEWARDSHIP

- Primary Goal: to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use
  - Consequences
    - Toxicity
    - Selection of pathogenic organisms
    - Emergence of resistant pathogens
- Secondary goal: to reduce health care costs without adversely affecting the quality of care



# VANCOMYCIN

## DONEC QUIS NUNC

- Internal audit → poor compliance with CDC Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines
  - CDC. Recommendations for preventing the spread of vancomycin resistance. MMWR 1995;44:RR-1
- Mandatory 72-hour stop time unless “vancomycin continuation form” was completed on return of culture and sensitivity data
- Agent was discontinued if patient did not meet criteria within 72 hours
- ID consult required to override automatic discontinuation

# Bad Bugs: No ESKAPE

- Enterococcus
- S. aureus
- Klebsiella spp.
- Acinetobacter
- P. aeruginosa
- Enterobacter spp.



ESCAPE: RECENT LITERATURE SUGGESTS WE SHOULD BE EXPANDING THIS LIST TO INCLUDE "C" FOR C DIFF DUE TO INCREASED PREVALENCE AND LACK OF APPROPRIATE ANTIMICROBIALS

Boucher H, et al, Clin Infect Dis 2009;48:1-12  
Patterson, et al, Clin Infect Dis 2009;49:992-3

# WHAT IS ANTIMICROBIAL STEWARDSHIP


ULTIMATE GOAL IS IMPROVED PATIENT CARE AND  
HEALTHCARE OUTCOMES



Dellit TH, et al. CID 2007;44:159-77,  
Hand K, et al. Hospital Pharmacist 2004;11:459-64  
Paskovaty A, et al IJAA 2005;25:1-10

# BUILDING THE TEAM

## Building the Stewardship team



# ANTIMICROBIAL STEWARDSHIP STRATEGIES

- Front end: Formulary restriction and preauthorization
- Back end: Interventions after antimicrobials have been prescribed
- BOTH: Prospective audit with intervention and feedback

Dellit TH, et al. CID 2007;44:159-77

Hand K, et al Hospital Pharmacist 2004;11:459-64

Paskovaty A, et al IJAA 2005;25:1-10

# • SUPPLEMENTAL STRATEGIES

- Education, guidelines, clinical pathways
- Dose optimization via PK-PD
- De-escalation/Streamlining
- Antimicrobial order forms/order sets
- IV-PO switch
- Computerized decision support
- Antimicrobial cycling
- Combination therapy

# "FRONT END"

- **Restriction at the time the antimicrobial is prescribed:**
  - **Formulary vs non-formulary**
  - **Target specific antimicrobials associated with high rates of resistance or \$  
\$\$**
  - **May target a specific disease or indication**
- **In order to receive restricted antibiotics, a prescriber must discuss with stewardship team**
- **performed by either an infectious diseases physician and/or a clinical pharmacist with infectious diseases training**
- **Requires resources early in the intervention process**

# “BACK END”

- **Prescribers are allowed to order antibiotics upon admission**
- **Antibiotic orders are reviewed at specified intervals after initiation**
- **May be restricted to particular patient populations**
  - **Ex: Tazocin in ICU for up to 72 hours**
  - **Ex: Echinocandins in Febrile Neutropenia**
- **May be restricted to formulary drugs or by using a clinic pathway or protocol**
  - **Ex: Pneumonia protocol**

Evidence Based

Improve patient  
safety

**ANTIMICROBIAL STEWARDSHIP PROGRAMS**

Improve community  
resistance profiles

Financially  
self-supporting



# BARRIERS TO IMPLEMENTING ASP

- Staff may not want to assume “added” responsibility without compensation
- Hospital administration may not pay for antibiotic management without guaranteed pharmacy savings
- Damaged relations could lead to decreased request for consultation and lost income
- only 18% of infectious diseases physicians participating in antimicrobial stewardship programs are reimbursed for their services,

# TOOLS FOR SUCCESS

- Multidisciplinary team
- Periodic feedback to physicians regarding program's benefits
- Focused goals



مستشفى جمعية المقاصد الخيرية الإسلامية - القدس  
Makassed Islamic Charitable Hospital Jerusalem  
Infectious Diseases Unit  
Antibiotics stewardship Program

Day:- ..... Date:-...../...../.....

**Patient information:**

Name: \_\_\_\_\_ File no. \_\_\_\_\_ Admission Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
Ward: \_\_\_\_\_ Gender: \_\_\_\_\_ Age: \_\_\_\_\_ Wt (kg): \_\_\_\_\_  
Allergies to antimicrobial:  no allergy  not documented  Present (specify drug and nature): \_\_\_\_\_

**Clinical information:**

Admitting diagnosis: \_\_\_\_\_  
WBC: \_\_\_\_\_ SrC: \_\_\_\_\_ CrCl(ml/min): \_\_\_\_\_ CRP: \_\_\_\_\_ Other lab tests: \_\_\_\_\_

**Microbiology:**

Blood culture: \_\_\_\_\_  
Urine culture: \_\_\_\_\_  
Screening: \_\_\_\_\_  
Other cultures: \_\_\_\_\_

**Antibiotic information:**

Antibiotic #1		Antibiotic #2		Antibiotic #3		Antibiotic #4	
Start	Stop	Start	Stop	Start	Stop	Start	Stop
/ /	/ /	/ /	/ /	/ /	/ /	/ /	/ /
Indication:		Indication:		Indication:		Indication:	

**Note:-**



مستشفى جمعية المقاصد الخيرية الإسلامية – القدس  
Makassed Islamic Charitable Hospital Jerusalem  
Infectious Diseases Unit

## Antibiotics, Antifungal & Antiviral Prices

Antimicrobial	NIS	Antimicrobial	NIS
Acyclovir (Zovirax) 250 mg IV	(13)		
Amikacin 500mg vial	(14)		
Amphotericin B (Fungizone) 50 mg IV	(80)		
Ampicillin (Penibrin) 1g vial	(7)	Ampicillin (Penibrin) 500mg vial	(6)
Amoxicillin/ Clavulinate (Augmentin) 875mg 14 tab	(25)	Amoxicillin/Clavulinate (Augmentin) 500mg 20 tab	(22)
Azithromycin 500mg vial	(110)	Azithromycin (Azimex) 500mg 6 tab	(27)
Caspofungin (Cancidas) 50 mg	(2177)	Caspofungin (Cancidas) 70mg	(2767)
Cefazoline 1g vial	(8)		
Ceftazidime (Fortum) 1g vial	(18)		
Cefotaxime (Claforan) 1g vial	(27)		
Ceftriaxone (Rocephin, Pan-Ceftriaxone) 1g	(7)		
Cefuroxime (Zinacef, Pan-Cefuroxime) 1 g vial	(6)	Cefuroxime (Zinnat) 500mg 10 tab	(25)
Ciprofloxacin (Ciproxin) vial	(20)	Ciprofloxacin 500 (ciprodex) 10 tab	(25)
		Ciprofloxacin 250 10 tab	(19)
Clindamycin 600mg amp	(15)	Clindamycin 150mg 16 tab	(20)
Cloxacillin (Orbenil) 500mg vial	(5)		
Colistin 1mil unit vial	(20)		
Doxycycline (Doxylin) 100mg 10tab	(14)		
Ertapenem (Invanz) 1g vial	(230)		
Fluconazole 100 mg IV	(32)		
Fusidic acid (Fucidin 2% cream 15g)	(22)	Fucidin-H 15g cream	(24)
Fusidic acid/ Betamethasone (Fucicort 15g cream)	(30)		
Gentamicin 80mg amp	(5)		
Imipenem and Cilastatin (Tienam) 500mg vial	(48)		
Levofloxacin (Tavanic) vial 500mg	(158)	Levofloxacin (Tavanic) 500mg 7 tab	(60)
Linezolid (Zyvox) 600mg IV	(690)		
Meropenem 1g vial	(53)		
Metronidazole (Flagyl) 500mg	(5)		
Miconazole cream 2%	(16)	Miconazole/ Daktazole cream	(10)
Moxifloxacin 400mg vial	(180)		
Mupirocin 2% 15g oint	(20)	Mupirocin Bactroban nasal	(23)
Penicillin G 5000000 IU vial	(15)	Penicillin VK 250mg 28 tab	(22)

قسم جراحة الاعصاب		Day care \ الطوارئ		العيادات	
.1		.1		.1	
.2		.2		.2	
.3		.3		.3	
.4		.4		.4	
قسم النسائية والتوليد		قسم الخداج		قسم العناية المركزة	
.1		.1		.1	
.2		.2		.2	
.3		.3		.3	
.4		.4		.4	
قسم انعاش الاطفال		قسم الاطفال		قسم الجراحة	
.1	.4	.1	.4	.1	.4
.2	.5	.2	.5	.2	.5
.3	.6	.3	.6	.3	.6
انعاش جراحة الاعصاب		قسم العظام			
.1		.1		.4	
.2		.2		.5	
.3		.3		.6	
قسم قلب كبير		قسم الباطني			
.1	.4	.1		.4	
.2	.5	.2		.5	
.3	.6	.3		.6	
قسم قلب صغير		قسم عناية القلب			
.1	.4	.1		.4	
.2	.5	.2		.5	
.3	.6	.3		.6	



مستشفى جمعية المقاصد الخيرية الإسلامية - القدس

Makassed Islamic Charitable Hospital –Jerusalem  
Infectious Diseases Unit

# Time to sample Drug Level

- ❖ **Peak concentration:** 30 minutes to 1 hour after the end of the infusion.
  - For Gentamicin multiple daily doses 30 minutes after the end of the infusion of the 4<sup>th</sup> dose.
  - For Gentamicin once daily dose 30 minutes after the end of the infusion of any dose.
  - For Vancomycin 1 hours after the end of the infusion.
  
- ❖ **Trough concentration:** 30 minutes before giving the next dose.
  - For Gentamicin multiple daily doses 30 minutes before 4<sup>th</sup> dose.
  - For Gentamicin once daily dose 30 minutes before next dose.
  - For Vancomycin 30 minutes before 4<sup>th</sup> dose.

# ANTIMICROBIAL STEWARDSHIP FOR THE ICP



- Assistant with early identification of organisms and infected patients to further the mission of stewardship program.
- Plays a pivotal role in the development, justification, and impact measurement of an antimicrobial stewardship program.
- Can promote compliance with standard and transmission-based precautions, bundle-care practices, vaccination efforts, and hand hygiene.
- Educating staff, patients, and visitors.

# CONCLUSIONS

- Antimicrobial stewardship can play a key role in the reduction of *C difficile* infection
- Implementing successful stewardship programs involves multiple strategies, administrative support, and effective collaboration of a multidisciplinary team
- Every ounce of stewardship counts – start small, think big!
- Infection preventionists can enhance stewardship efforts through patient identification, prevention of device-related infections, and through input in the development of drug and disease state bundles.